
Product Data Sheet

Product Name: SKF 83959

Cat. No.: GC69910

Chemical Properties

Cas. No. 80751-85-5

Formula $C_{18}H_{20}ClNO_2$

M.Wt 317.81

Solubility DMSO : ≥ 100 mg/mL (314.65 mM)

Storage Store at $-20^{\circ}C$

General tips For obtaining a higher solubility , please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

SKF83959 is a potent and selective dopamine **D₁-like** receptor partial agonist.

SKF83959 **K_i** values for rat **D₁**, **D₅**, D₂ and D₃ receptors are 1.18, 7.56, 920 and 399 nM, respectively. SKF83959 is a potent allosteric modulator of **sigma (σ)-1** receptor. SKF83959 belongs to benzazepine family and has improvements on cognitive dysfunction. SKF83959 can be used for the research of Alzheimer's disease and depression^{[1][2][3][4]}.

SKF83959 (10~250 μ M) stimulates PIP2 drolysis in membranes. SKF83959 (0.1~10 μ M; PC12 cell) changes the EC₅₀ value of SKF81297 from 0.5 nM in control tissue to 31.6 nM, 251.2 nM and 631.0 nM^[2].

SKF83959 (0.5 and 1 mg/kg; i.p.; 1 hour) reverses the scopolamine-induced cognitive impairments in the passive avoidance task and Y-Maze test^[1].

SKF83959 (1 mg/kg; i.p.; 30 minutes) induced memory enhancing effects are prevented by brain-derived neurotrophic factor system blockade^[1].

SKF83959 has anti-amnesic activities and restores the scopolamine-decreased BDNF signaling pathway in the hippocampus in mice^[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Animal Model: Male ICR male mice (8 weeks)^[1]

Dosage: 0.5 and 1 mg/kg

Administration: I.p.; 1 hour

Result: Reversed the scopolamine-induced cognitive impairments in the passive avoidance task and Y-Maze test.

Animal Model: Male ICR male mice (8 weeks)^[1]

Dosage: 1 mg/kg

Administration: I.p.; 30 minutes

Result: The memory enhancing effects were prevented by BDNF system blockade.

[1]. Sheng G, et al. SKF83959 Has Protective Effects in the Scopolamine Model of Dementia. Biol Pharm Bull. 2018;41(3):427-434.

[2]. Jin LQ, et al. SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J Neurochem. 2003;85(2):378-386.

[3]. Neumeyer JL, et al. Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol. 2003;474(2-3):137-140.

[4]. Guo L, et al. SKF83959 is a potent allosteric modulator of sigma-1 receptor. Mol Pharmacol. 2013;83(3):577-586.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA